This information is intended to provide a general overview of Inflammatory Breast Cancer (IBC). It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health.
Inflammatory Breast Cancer (IBC) is a distinct and aggressive form of breast cancer that requires specialised treatment. Unlike more common types, it does not typically present as a lump, but instead causes visible changes to the breast.
IBC is a rare and fast-growing disease. Its characteristic symptoms are not caused by infection or inflammation, but by cancer cells obstructing the small lymph vessels within the skin and soft tissue of the breast. This blockage causes lymph fluid to build up, leading to rapid swelling and the noticeable changes in the breast's appearance.
Like other breast cancers, IBC is categorised into molecular subtypes, which help guide treatment and determine prognosis. These subtypes include: HER2-positive, hormone receptor-positive, and triple-negative. Compared to non-inflammatory breast cancer, IBC is more frequently HER2-positive or triple-negative, both of which are aggressive subtypes.
While historically reported with a low five-year survival rate, advances in care have significantly improved outcomes. Recent studies indicate that with appropriate treatment, the five-year survival rate for IBC is now closer to 70% for Stage III patients and up to 50% for newly diagnosed Stage IV patients.
IBC is always considered at least a Stage III cancer upon diagnosis. If the disease has spread beyond the breast and nearby lymph nodes to distant parts of the body, it is classified as Stage IV.
The risk factors for IBC are largely the same as for other forms of breast cancer. These include:
IBC symptoms often appear very quickly, usually developing over a period of days or weeks. Most women diagnosed with IBC do not feel a distinct lump.
While these symptoms do not definitively mean a diagnosis of inflammatory breast cancer, it is crucial to discuss any changes with a doctor promptly, as they may indicate other serious health issues.
An early and accurate diagnosis is essential for the successful treatment of this fast-growing disease.
Since IBC symptoms can mimic those of mastitis (a breast infection), doctors may first prescribe antibiotics. If the symptoms do not improve or worsen, further diagnostic tests are pursued immediately.
The initial diagnostic procedures typically include a mammogram, breast ultrasound, and breast MRI. A PET CT (a combined PET scan and CT scan) is often used for IBC patients to check for disease spread, more so than a standard CT scan or bone scan.
As a lump may not be present, imaging may show signs such as skin thickening or enlarged lymph nodes. An image-guided core needle biopsy is the standard procedure to retrieve and examine suspected cancerous tissue under a microscope. A skin biopsy may also be necessary in some cases to determine the extent of the disease.
If cancer is confirmed, the cells are then analysed to determine the disease's molecular receptor subtype (Estrogen, Progesterone, and HER2 status). This information is vital for developing a comprehensive, personalised treatment plan.
The treatment for inflammatory breast cancer is complex and often involves a multimodal approach (a combination of different therapies) due to its aggressive nature. Treatment plans are tailored to the individual patient, considering the disease stage and molecular subtype.
For disease that has not spread beyond the regional lymph nodes, treatment typically follows a defined sequence:
Administered first to shrink the tumour and simplify the subsequent surgery.
A complete mastectomy (removal of the entire breast) is usually necessary, along with the removal of nearby lymph nodes. Lumpectomy is not an option for IBC. Breast reconstruction is typically postponed until all cancer therapy is complete and there is no evidence of disease.
Given after surgery to the chest wall and lymph nodes to eliminate any remaining cancer cells and reduce the risk of local recurrence.
Administered based on the tumour's molecular subtype.
If the cancer has spread to distant sites, treatment usually begins with chemotherapy. If the tumour responds well, a mastectomy may then be considered. Additional treatments include targeted therapy, radiation therapy, and immunotherapy.
Uses potent drugs to kill, control the growth of, or relieve pain caused by cancer cells. It is given both before and after surgery.
A Mastectomy is the standard surgical option. Surgeons usually remove nearby lymph nodes as well. Breast reconstruction is not recommended immediately following surgery.
Uses high-energy beams to destroy cancer cells. It is commonly delivered to the chest wall and lymph nodes after chemotherapy and surgery to lower the risk of recurrence.
These therapies specifically interfere with the molecules that cancer cells rely on to grow and spread.
A treatment that harnesses the patient's own immune system to fight the cancer. Its use in breast cancer is currently approved in specific, limited cases, with ongoing research to expand its application.
Since IBC is rare (1-5% of all breast cancer cases), the success of treatment is highly dependent on an experienced care team. At SSCHRC, our doctors treat hundreds of IBC patients every year, providing deep expertise from initial diagnosis through metastatic or recurrent disease. This experience leads to better surgical outcomes, with SSCHRC reporting high success rates in surgical margins, which significantly lowers the risk of local recurrence. Furthermore, SSCHRC surgeons are leaders in specialised procedures to prevent or reverse lymphedema, a common side effect for IBC patients. Clinical trials offering the latest drugs, including targeted therapy and immunotherapy options, are also available for patients at all stages of IBC.